The Future of 5-MeO-DMT: Numinus x F.I.V.E.
With Payton Nyquvest, Dr. Paul Thielking, Hannah Cross, Joel Brierre & Victoria Wueschner
Enter your email to watch
Get instant access to every FIVE seminar recording, plus new research, seminar dates and recordings in your inbox.
What you'll learn
- Why 5-MeO-DMT is a focus of drug development right now, and what early clinical data is showing
- Risks and adverse events seen in clinical trials
- Why trained, two-person support matters, including seizure-like movement and injury risk
- Medical and transformational models of 5-MeO-DMT work, and how they differ
- Preparation for existential fears, and the integration and ethics the field needs next
Information shared by seminar speakers does not necessarily represent the views, thoughts, and opinions of The FIVE Institute.